Literature DB >> 8747767

Infection in the organ transplant recipient. An overview.

D P Kontoyiannis1, R H Rubin.   

Abstract

Considerable progress has been made in elucidating the factors involved in the pathogenesis of infection in the organ transplant patient. One of the general principles that has emerged is that the risk of clinical infection, particularly opportunistic infection, is determined largely by the interaction between the patient's net state of immunosuppression and the epidemiologic exposures the patient encounters. The two major factors that determine the net state of immunosuppression are the nature of the exogenous immunosuppressive therapy that is administered and whether or not infection is present with one or more of the immunomodulating viruses (particularly cytomegalovirus, Epstein-Barr virus, and the hepatitis viruses). Finally, the therapeutic prescription for the transplant patient has two components--an immunosuppressive component to prevent and treat rejection and an antimicrobial component, which is linked to the intensity of the immunosuppressive therapy required, to make this safe. This reflects the recognition that the two major barriers to successful transplantation, rejection and infection, are closely tied together by the current requirement for lifelong immunosuppressive therapy. Progress in one area will have beneficial effects on the other.

Entities:  

Mesh:

Year:  1995        PMID: 8747767

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  3 in total

1.  Ocular complications in heart, lung and heart-lung recipients.

Authors:  Toks Akerele; Susan Lightman
Journal:  Br J Ophthalmol       Date:  2006-10-11       Impact factor: 4.638

2.  Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.

Authors:  J A Mauskopf; A Richter; L Annemans; G Maclaine
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

Review 3.  Viral prophylaxis in organ transplant patients.

Authors:  Michelle Slifkin; Shira Doron; David R Snydman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.